Bicara Therapeutics Inc.
BCAX Nasdaq
SEC CIK 2023658
Follow Bicara Therapeutics
Weekly email: filings, results
Net income
−$71.2M
−96.1% vs same quarter last year
EPS, diluted
−$1.04
−55.2% vs same quarter last year
Operating cash flow
−$56.1M
−91.9% vs same quarter last year
Operating income
−$75.7M
−86.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$138M |
| FY24 | −$68M |
| FY23 | −$52M |
| FY22 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$107.1M |
| FY24 | −$74.8M |
| FY23 | −$46.2M |
| FY22 | - |